Across the globe, medical device and diagnostic companies are experiencing new levels of price resistance and competitive pressure. No one wants to spend more than they already do – unless they’re given a compelling reason. The only counter to that pressure is compelling evidence of differentiated value. Once considered nice-to-have, Evidence Generation has become as crucial as any other key success factor.

At the same time, companies have been forced to reduce revenue projections and institute widespread budget cuts as they deal with macroeconomic and supply chain pressures. Unfortunately, just as evidentiary standards for pricing, reimbursement, and adoption are increasing, many companies have reduced or eliminated needed resources. As budgets become tighter, organizations will need to approach evidence generation in a way that ensures the right evidence is developed while optimizing the resource spend.